X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (594) 594
index medicus (462) 462
clinical neurology (454) 454
male (381) 381
female (376) 376
middle aged (326) 326
aged (285) 285
symptomatic vasospasm (273) 273
stroke (261) 261
surgery (251) 251
subarachnoid hemorrhage (233) 233
treatment outcome (184) 184
adult (183) 183
risk factors (173) 173
neurosciences (160) 160
retrospective studies (148) 148
subarachnoid hemorrhage - complications (147) 147
neurology (127) 127
aged, 80 and over (126) 126
peripheral vascular disease (118) 118
symptomatic intracerebral hemorrhage (113) 113
hemorrhage (109) 109
ischemia (107) 107
vasospasm (104) 104
risk (100) 100
management (99) 99
vasospasm, intracranial - etiology (96) 96
acute ischemic-stroke (93) 93
medicine & public health (92) 92
tomography, x-ray computed (90) 90
thrombolysis (86) 86
therapy (85) 85
cerebral vasospasm (84) 84
tissue-plasminogen activator (84) 84
stroke - drug therapy (82) 82
symptomatic intracranial hemorrhage (81) 81
time factors (79) 79
neurosurgery (77) 77
care and treatment (71) 71
prognosis (71) 71
aneurysmal subarachnoid hemorrhage (69) 69
intravenous thrombolysis (67) 67
prospective studies (67) 67
magnetic resonance imaging (65) 65
aneurysms (64) 64
diagnosis (64) 64
thrombolytic therapy (64) 64
angioplasty (60) 60
intracranial aneurysm - complications (60) 60
mortality (59) 59
radiology, nuclear medicine & medical imaging (59) 59
analysis (58) 58
blood-flow (58) 58
thrombolytic therapy - adverse effects (58) 58
intracranial hemorrhage (57) 57
predictive value of tests (57) 57
symptomatic patients (57) 57
cerebral angiography (56) 56
brain (55) 55
neuroimaging (53) 53
stroke - etiology (53) 53
subarachnoid hemorrhage - diagnostic imaging (53) 53
aneurysm (51) 51
brain ischemia - drug therapy (50) 50
severity of illness index (50) 50
transcranial doppler (50) 50
prevention (48) 48
endarterectomy (47) 47
endovascular treatment (47) 47
patients (47) 47
subarachnoid hemorrhage - surgery (47) 47
tissue plasminogen activator - adverse effects (46) 46
alteplase (45) 45
fibrinolytic agents - adverse effects (45) 45
risk-factors (45) 45
acute ischemic stroke (44) 44
brain ischemia - complications (44) 44
computed-tomography (44) 44
vasospasm, intracranial - diagnostic imaging (44) 44
angiography (43) 43
brain ischemia - etiology (43) 43
outcome (43) 43
stenosis (42) 42
trial (42) 42
animals (41) 41
ischemic stroke (41) 41
usage (41) 41
cohort studies (40) 40
fibrinolytic agents - administration & dosage (40) 40
infarction (40) 40
intracerebral hemorrhage (40) 40
blood (39) 39
research (39) 39
tissue plasminogen activator (39) 39
vasospasm, intracranial - therapy (39) 39
outcomes (38) 38
stents (38) 38
adolescent (37) 37
cerebral ischemia (37) 37
stroke - diagnosis (37) 37
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (774) 774
Japanese (34) 34
French (5) 5
German (5) 5
Spanish (4) 4
Czech (2) 2
Polish (2) 2
Chinese (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Stroke, ISSN 0039-2499, 06/2009, Volume 40, Issue 6, pp. 1963 - 1968
Journal Article
Cerebrovascular Diseases, ISSN 1015-9770, 09/2012, Volume 34, Issue 2, pp. 106 - 114
Background: Symptomatic intracranial hemorrhage (SICH) is a devastating complication of intravenous thrombolysis treatment that is associated with high... 
Review | Recombinant tissue plasminogen activator | Symptomatic intracranial hemorrhage | Ischemic stroke | SAFETY | RISK | CLASSIFICATION | CLINICAL NEUROLOGY | THERAPY | TISSUE-PLASMINOGEN-ACTIVATOR | INTRACEREBRAL HEMORRHAGE | PERIPHERAL VASCULAR DISEASE | EXPERIENCE | 3 H | CANADIAN ALTEPLASE | CLINICAL-PRACTICE | Recombinant Proteins - therapeutic use | Humans | Middle Aged | Male | Tissue Plasminogen Activator - therapeutic use | Recombinant Proteins - adverse effects | Tissue Plasminogen Activator - adverse effects | Cerebral Hemorrhage - diagnosis | Incidence | Fibrinolytic Agents - adverse effects | Registries - statistics & numerical data | Fibrinolytic Agents - therapeutic use | Female | Cerebral Hemorrhage - chemically induced | Severity of Illness Index | Multicenter Studies as Topic - statistics & numerical data | Randomized Controlled Trials as Topic - statistics & numerical data | Cerebral Hemorrhage - mortality | Tissue Plasminogen Activator - administration & dosage | Recombinant Proteins - administration & dosage | Brain Damage, Chronic - etiology | Brain Ischemia - drug therapy | Aged | Brain Damage, Chronic - epidemiology | Fibrinolytic Agents - administration & dosage | Infusions, Intravenous | Thrombolytic Therapy - adverse effects | Cerebral Hemorrhage - complications | Research Design | Cohort Studies | Neuroimaging | Stroke | Demography | Intravenous administration | Mortality | Clinical trials | Data processing | Hemorrhage | Bleeding | t-Plasminogen activator | Neurological diseases | Databases | Ischemia | Hematoma | thrombolysis | Standard deviation | Cerebrovascular diseases | Age
Journal Article
European Journal of Neurology, ISSN 1351-5101, 02/2018, Volume 25, Issue 2, pp. 340 - e11
Background and purpose Intravenous thrombolysis (IVT) is the only approved pharmacological treatment for acute ischemic stroke. Off‐label IVT for ischemic... 
intravenous thrombolysis | off‐label | ischemic stroke | symptomatic intracranial haemorrhage | off-label | MISSING DATA | SITS-MOST | NEUROSCIENCES | CLINICAL NEUROLOGY | PLASMINOGEN-ACTIVATOR | ALTEPLASE | ACUTE ISCHEMIC-STROKE | MINOR STROKE | MULTIPLE IMPUTATION | RETROSPECTIVE ANALYSIS | EXCLUSION CRITERIA | Cerebral Hemorrhage - chemically induced | Humans | Middle Aged | Europe - epidemiology | Thrombolytic Therapy - statistics & numerical data | Male | Stroke - drug therapy | Tissue Plasminogen Activator - adverse effects | Fibrinolytic Agents - standards | Fibrinolytic Agents - adverse effects | Cerebral Hemorrhage - epidemiology | Intracranial Hemorrhages - chemically induced | Female | Registries | Stroke - epidemiology | Aged | Retrospective Studies | Thrombolytic Therapy - standards | Thrombolytic Therapy - adverse effects | Off-Label Use - standards | Off-Label Use - statistics & numerical data | Tissue Plasminogen Activator - standards | Stroke (Disease) | Drug therapy | Analysis | Hypertension | Stroke | Intravenous administration | Statistical analysis | Diabetes mellitus | Disorders | Health risks | Pharmacology | Criteria | Regression analysis | Hemorrhage | Patients | Thrombolysis | Blood | Neurological diseases | Confidence intervals | Ischemia | Blood pressure | Safety | Books | Neurological disorders
Journal Article
Journal of Stroke and Cerebrovascular Diseases, ISSN 1052-3057, 11/2019, Volume 28, Issue 11, p. 104363
Journal Article
Journal Article
Journal Article
Journal of Stroke and Cerebrovascular Diseases, ISSN 1052-3057, 2016, Volume 26, Issue 4, pp. 766 - 771
Background The symptomatic intracranial hemorrhage (SICH) is a serious complication of endovascular therapy (EVT) in acute ischemic stroke (AIS) with large...